JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Clinical trial NCT07518160 · RECRUITING

Trial details

NCT number: NCT07518160
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Start date: 2026-04-21
Primary completion: 2028-04-23
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.